New Report Forecasts That Pharmaceutical Industry Ethical Sales Will Increase at a Modest 3.2% CAGR 2006 to 2012
Posted on: Thursday, 7 February 2008, 12:00 CST
Research and Markets (http://www.researchandmarkets.com/reports/c81917) has announced the addition of Datamonitor's new report: The Pharmaceutical Company Outlook to 2012: Strategic Analysis of the Sales Outlook for Big Pharma, Mid Pharma, Japan Pharma and Biotech to their offering.
Based on an analysis of 43 companies and 1,200+ products, Datamonitor forecasts that pharmaceutical industry ethical sales will increase at a modest 3.2% CAGR 2006 to 2012. However, behind this industry average figure there are strategic segments of the market that offer double-digit growth rates through barriers against generic competition and the opportunity for aggressive indication broadening.
Scope
Strategic Analysis of the Sales Outlook to 2012 for Big Pharma, Mid Pharma, Japan Pharma and Biotech
Quantitative analysis of the revenue balance of launches and expiries for each peer set member to 2012
Assessment of current and forecast 2012 therapy area sales and molecule type focus for each peer set member
Highlights of this title
Faced with failing growth, Big Pharma is expected to pursue strategic options including operational cost efficiencies, M&A with other Big Pharma companies, biotech, Mid Pharma CNS players and/or generics manufacturers and acquisitional moves outside of pharma space to increase presence in medical devices, diagnostics and consumer healthcare.
Key reasons to purchase this title
Understand the strategic motives behind the recent wave of Big Pharma acquisitions of monoclonal antibody companies
Identify the rare examples of promising high growth CNS products located in the Mid Pharma peer set
Learn how biotech faces slowing growth momentum due to commercial pressures on therapeutic proteins
Companies Mentioned;
Abbott Laboratories
Amgen Inc.
Applied Signal Technology Inc
Astellas Pharma
AstraZeneca PLC
Bayer Schering Pharma AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Cephalon
Chugai Pharmaceutical Co. Ltd
Daiichi Sankyo, Ltd.
Dainippon Sumitomo Pharma Co., Ltd.
Eli Lilly and Company
Forest Laboratories, Inc
Genentech, Inc.
Genzyme Corporation
Gilead Sciences, Inc.
GlaxoSmithKline Plc
IMS Health
Johnson & Johnson
King Pharmaceuticals, Inc
Merck & Co., Inc.
Merck KGaA
Novartis AG
Novo Nordisk A/S
Nycomed International Management GmbH
Pfizer Inc
Sanofi-Aventis
Schering-Plough Corporation
Schwarz Pharma AG
Sepracor Inc.
Servier
Shionogi & Co., Ltd.
Shire plc
Software House Intl
Solvay Group
Wyeth
For more information visit http://www.researchandmarkets.com/reports/c81917
Source: Datamonitor
Source: Business Wire
Related Articles
- Research and Markets: Pacific Gas and Electric Company Detailed Analysis and Forecasts of Oil & Gas Exploration and Production Assets is Out Now
- Research and Markets: Pioneer Natural Resources Company (Pioneer) Analysis Across The Oil and Gas Value Chain: An Essential Source for Data
- Monterey Gourmet Foods Partners With Acosta Sales and Marketing Company
- Ibis Technology Selects Investment Banker to Pursue Potential Sale of the Company
- InsideSales.Com Hires Jeff Adcock As Vice President of Strategic Alliance Sales
- JupiterResearch Reports That Large and Mid-Sized Companies Lag in Mastering Word of Mouth Marketing Strategies
- Health Net of California Promotes Lori Scott to Vice President of Commercial Sales-Mid Market and Appoints Gina Stassi Vice President of PPO Product Management
- Spectrum Announces Strategic Alliance With Par Pharmaceutical Companies, Inc. For Sales and Distribution of Spectrum's Generic Product Line
- TargetRx Wins Eastern Technology Council's Enterprise Award for Life Sciences Growth Company of the Year
- Verticalnet Enables Mid-Market Companies to Lower Material Costs With Comprehensive Supply Management Solutions
 |
 |
User Comments (0)
RSS Feeds